Right now my best-selling gold research service is sitting on average open gains of 519%.
There’s one exception: a tiny gold company I most recently added to the portfolio. It’s still only up 19%.
It’s currently my favorite buy across all of my research.
I believe this company could realistically soar 400% in early 2026.
The truth is, I was preparing an investment brief on this company all last week… this brief is now live, but with the correction in gold, all of the numbers and analysis I did mean the company is now selling at an even bigger discount than it was last week.
It’s selling for about an 80% discount to my fair value estimate…
But I’m convinced the market will revalue this company as soon as it produces its first ounces of gold in early 2026.
That means you only have weeks to get in…
And this latest correction gives you the perfect entry point.
Don’t miss out on this opportunity.
See my full write-up on my #1 favorite gold stock here.
Best,
Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio
Breakout Momentum Plays You Need to Know About
Written by Nathan Reiff. Published 10/23/2025.
Key Points
- Three companies with momentum potential include two biotech firms—uniQure and Omeros—and a maker of battery-grade lithium products, Stardust Power.
- uniQure and Omeros have seen significant product developments, either in the form of promising results or through licensing agreements.
- Stardust is expanding its supply of lithium carbonate and is poised to ramp up production at a time when federal regulations are an important tailwind for the industry.
Momentum investors rely on a combination of careful analysis, timing and discipline to maximize gains. While this approach carries risk, the lure of identifying a fast-growing stock and joining a rally with room to run is powerful.
The biopharmaceutical industry's potential for explosive growth makes it a primary target for many momentum investors, and two companies in that sector have recently posted significant gains. The first, uniQure N.V. (NASDAQ: QURE), saw a major share-price leap in late September and has extended those gains since. The other, Omeros Corp. (NASDAQ: OMER), jumped in mid-October.
Solving a Trillion-Dollar Problem with AI - and You Can Own a Piece (Ad)
Solving a Trillion-Dollar Problem with AI – and You Can Own a Piece
With backing from Adobe and major investors, RAD Intel is gaining momentum fast. They've secured a potential Nasdaq ticker, and shares are still available at $0.81.
For investors seeking diversification outside the biotech space, Stardust Power Inc. (NASDAQ: SDST) is a micro-cap battery-tech company and penny stock that has yet to begin a rally but offers dramatic upside potential according to bullish analysts.
Large Pipeline and Promising Results Fuel uniQure
Known for its adeno-associated viral (AAV) vector platform used to develop gene therapies for diseases including hemophilia, uniQure reported encouraging results in September from an initial safety and exploratory efficacy trial of its AMT-191 candidate. The company also has several other promising candidates: AMT-130 received breakthrough therapy designation earlier this year and has shown strong results in patients with Huntington's disease, while AMT-260 produced a significant reduction in seizures in patients with a rare form of epilepsy.
As a pre-profit biotech, uniQure must maintain a healthy cash position to fund development and trials. At the end of the second quarter, the company reported $377 million in cash and investments, providing a runway into 2027 and extending past AMT-130's projected launch window.
QURE shares have traded sideways since the September spike, but analysts remain bullish. Ten of 12 rate the stock a Buy, and the consensus price target is $71.75, implying roughly 15% upside.
Major Novo Nordisk Deal Launches Opportunities for Omeros
Omeros develops small-molecule and protein therapeutics targeting central nervous system conditions. One of its most promising drugs, Zaltenibart, has potential applications in several blood and kidney disorders.
In mid-October, shares spiked when the company announced Danish pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) had acquired licensing rights to Zaltenibart for $240 million in upfront payments plus potential additional royalties.
The deal also strengthens Omeros' balance sheet; with a runway into 2027, the company has more time to pursue FDA approval for another lead candidate, narsoplimab.
After jumping from just over $4 per share to nearly $11 on the Novo Nordisk news, OMER shares have since retreated to around $8. Still, analysts are optimistic: five of eight rate OMER a Buy, and they see upside of nearly 244%, which would put the stock above $27 per share.
Key Agreements and Regulatory Tailwinds Could Mean 1,000% Upside for Stardust
Pre-profit companies are inherently risky, and Stardust may be an even higher-risk, higher-reward proposition. Just three years old and pre-revenue, this roughly $40 million lithium battery-product provider is down more than 87% year to date. However, recent commercial agreements may position the company for growth.
Stardust signed deals with Oklahoma Gas and Electric Company—a subsidiary of OGE Energy Corp. (NYSE: OGE)—to develop an electric substation, and with Prairie Lithium to secure 6,000 metric tons of lithium carbonate per year. Those agreements bring the company closer to scaling production at a time when domestic demand is rising and international trade tensions are constraining North American lithium supply.
Federal initiatives to support domestic lithium production have added additional tailwinds for companies like Stardust. That backdrop has encouraged bullish analyst calls: four of six analysts rate SDST a Buy, and the consensus price target of $51.13 is nearly 1,000% above current trading levels.
This message is a sponsored message for Golden Portfolio, a third-party advertiser of MarketBeat. Why did I receive this email?.
If you have questions or concerns about your newsletter, feel free to email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
Copyright 2006-2025 MarketBeat Media, LLC. All rights protected.
345 North Reid Place, Suite 620, Sioux Falls, SD 57103. U.S.A..
0 Response to "This gold stock is a screaming buy now"
Post a Comment